Abstract
Accumulating epidemiological, clinical, and experimental evidence demonstrates that chronic inflammation plays a critical role in multistep oncogenesis. While long-term users of selective cycloxygenase (COX)-2 inhibitors (- coxibs) and non-steroidal anti-inflammatory drugs (NSAIDs) exert a reduced risk of development of certain types of cancer, including colorectal cancer (CRC), the adverse gastrointestinal and cardiovascular side effects associated with these drugs have limited their daily use for cancer chemoprevention. The role of various proinflammatory mediators during carcinogenesis and their promise as potential targets for chemoprevention of inflammation-associated carcinogenesis has been recently highlighted. A variety of chemopreventive phytochemicals and phytonutrients are able to alter or correct undesired cellular functions caused by abnormal pro-inflammatory signal transmissions that are mediated by NF-kappaB, etc. Modulation of cellular signaling involved in chronic inflammatory responses, induced by anti-inflammatory agents, hence provides a rational and practical strategy in molecular target-based cancer chemoprevention. This short review will focus on the role of chronic inflammation in colorectal oncogenesis and introduce dietary cancer chemopreventive agents with anti-inflammatory activity.
Keywords: Colon carcinogenesis, inflammation, chemoprevension, flavonoid, carotenoid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Volume: 9 Issue: 2
Author(s): Yumiko Yasui and Takuji Tanaka
Affiliation:
Keywords: Colon carcinogenesis, inflammation, chemoprevension, flavonoid, carotenoid
Abstract: Accumulating epidemiological, clinical, and experimental evidence demonstrates that chronic inflammation plays a critical role in multistep oncogenesis. While long-term users of selective cycloxygenase (COX)-2 inhibitors (- coxibs) and non-steroidal anti-inflammatory drugs (NSAIDs) exert a reduced risk of development of certain types of cancer, including colorectal cancer (CRC), the adverse gastrointestinal and cardiovascular side effects associated with these drugs have limited their daily use for cancer chemoprevention. The role of various proinflammatory mediators during carcinogenesis and their promise as potential targets for chemoprevention of inflammation-associated carcinogenesis has been recently highlighted. A variety of chemopreventive phytochemicals and phytonutrients are able to alter or correct undesired cellular functions caused by abnormal pro-inflammatory signal transmissions that are mediated by NF-kappaB, etc. Modulation of cellular signaling involved in chronic inflammatory responses, induced by anti-inflammatory agents, hence provides a rational and practical strategy in molecular target-based cancer chemoprevention. This short review will focus on the role of chronic inflammation in colorectal oncogenesis and introduce dietary cancer chemopreventive agents with anti-inflammatory activity.
Export Options
About this article
Cite this article as:
Yasui Yumiko and Tanaka Takuji, Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (2) . https://dx.doi.org/10.2174/187152310791110661
DOI https://dx.doi.org/10.2174/187152310791110661 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Aberrant DNA Methylation and Prostate Cancer
Current Genomics Pharmacogenomics of Cytochrome P450 Enzymes in Tumours
Current Pharmacogenomics MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Anti-inflammatory and Antioxidant Agents from Salvia Genus (Lamiaceae): An Assessment of the Current State of Knowledge
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Using Compound Similarity and Functional Domain Composition for Prediction of Drug-Target Interaction Networks
Medicinal Chemistry Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging Medicinal Value and Potential Therapeutic Mechanisms of Gynostemma pentaphyllum (Thunb.) Makino and Its Derivatives: An Overview
Current Topics in Medicinal Chemistry COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pharmacologic Evidence of Green Tea in Targeting Tyrosine Kinases
Current Reviews in Clinical and Experimental Pharmacology Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Proline Oxidase (POX) as A Target for Cancer Therapy
Current Drug Targets Metabolomics as a Functional Tool in Screening Gastro Intestinal Diseases: Where are we in High Throughput Screening?
Combinatorial Chemistry & High Throughput Screening Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Carcinoembryonic Antigen as a Target to Induce Anti-Tumor Immune Responses
Current Cancer Drug Targets Withdrawal Notice: Application of Nanomaterials in Development of Electrochemical Sensors and Drug Delivery Systems for Anticancer Drugs
Current Drug Delivery Dihydropyrimidine Dehydrogenase Genotyping and Phenotyping for 5- Fluorouracil Dysmetabolism: Moving Towards Personalized Chemotherapy in Patients with Cancer
Current Pharmacogenomics and Personalized Medicine